CytomX Therapeutics
CTMX
CTMX
97 hedge funds and large institutions have $441M invested in CytomX Therapeutics in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
5.6% more ownership
Funds ownership: 60.15% → 65.75% (+5.6%)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
97
Holding in Top 10
1
Calls
$1K
Puts
$1K
Top Buyers
| 1 | +$9.49M | |
| 2 | +$7.41M | |
| 3 | +$4.5M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.07M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$3.7M |
Top Sellers
| 1 | -$5.74M | |
| 2 | -$4.5M | |
| 3 | -$4.48M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.36M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.33M |